Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)

The Quick Take
Sogroya® is a once-weekly treatment option for appropriate children 2.5 and older, offering an alternative to once-daily therapy, which may help address the common challenge of non-adherence associated with daily injections1 Approval based on results from the pivotal REAL8 clinical trial...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Cannabiz Seed: An emerging global cannabis seed brand putting genetics and community first
With a growing presence across North America, Australia, and Europe, Cannabiz Seed is building its reputation through quality cannabis genetics,…
Local
Spin Cycle: More Bally’s Drama Highlights Week In Gambling - Casino Reports
Spin Cycle: More Bally’s Drama Highlights Week In Gambling Casino Reports
Local
Hoymiles showcases versatile residential solar and storage solutions at RE+ 2026
LAS VEGAS, Nov. 20, 2026 /PRNewswire/ -- Hoymiles showcased its latest residential solar and energy storage solutions at RE+ 2026, featuring the HiFlow Pro…
Business
Rebecca Farnsworth Joins Mason Investment Advisory Services, Inc., as Senior Investment Consultant
Farnsworth brings more than 20 years of institutional investment experience, with a focus on nonprofit clients, to Mason's institutional consulting team.…
